Literature DB >> 6769747

Early diagnosis of alcoholic cirrhosis by the aminopyrine breath test.

J B Saunders, K O Lewis, A Paton.   

Abstract

The aminopyrine breath test was assessed as an indicator of liver damage in a consecutive series of 49 chronic alcoholics admitted for detoxification. Mean 14CO2 excretion for those with compensated cirrhosis was 1.6%, compared with 6.8% for those with histologically normal livers, 4.3% for those with fatty change, and 4.0% for those with fatty change and fibrosis. All patients with cirrhosis had a value below the lower limit of normal (3.2%), whereas only 6 of the other patients had a subnormal value. Repeat studies after 7-10 days' abstinence showed that 14CO2 excretion increased in patients with compensated cirrhosis. In view of the poor prognosis of alcoholic cirrhosis once decompensation occurs, early identification of those at risk is important. The aminopyrine breath test was found to be a conventient and sensitive method for detecting early cirrhosis and lends itself as a screening procedure in the management of alcoholic patients.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6769747

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  9 in total

1.  Drug pharmacokinetics and the carbon dioxide breath test.

Authors:  E A Lane; I Parashos
Journal:  J Pharmacokinet Biopharm       Date:  1986-02

2.  Effect of liver disease on the kinetics of lactate removal after heavy exercise.

Authors:  R Casaburi; S Oi
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1989

3.  Improvement of quantitative testing of liver function in patients with chronic hepatitis C after installment of antiviral therapy.

Authors:  Matthias Ocker; Marion Ganslmayer; Steffen Zopf; Susanne Gahr; Christopher Janson; Eckhart-G Hahn; Christoph Herold
Journal:  World J Gastroenterol       Date:  2005-09-21       Impact factor: 5.742

4.  Assessment of drug metabolism in hepatic disease: comparison of plasma kinetics of oral cyclobarbital and the intravenous aminopyrine breath test.

Authors:  U Breyer-Pfaff; H Seyfert; M Weber; E H Egberts
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

5.  Pharmacokinetics of caffeine in patients with decompensated type I and type II diabetes mellitus.

Authors:  T Zysset; H Wietholtz
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

6.  Aminopyrine breath test predicts surgical risk for patients with liver disease.

Authors:  R A Gill; M W Goodman; G R Golfus; G R Onstad; M P Bubrick
Journal:  Ann Surg       Date:  1983-12       Impact factor: 12.969

7.  Plasma levels of parent drug and metabolites in the intravenous aminopyrine breath test.

Authors:  U Breyer-Pfaff; M Harder; E H Egberts
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

8.  Breath 14CO2 after intravenous administration of [14C]aminopyrine in liver diseases.

Authors:  S Pauwels; A P Geubel; C Dive; C Beckers
Journal:  Dig Dis Sci       Date:  1982-01       Impact factor: 3.199

9.  [14C]Aminopyrine breath test in chronic liver disease: preliminary diagnostic implications.

Authors:  A V Burnstein; J T Galambos
Journal:  Dig Dis Sci       Date:  1981-12       Impact factor: 3.199

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.